Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

By G. Abou-Alfa, G. Lau, M. Kudo, S. Chan, R. Kelley, J. Furuse, W. Sukeepaisarnjaroen, Yoon-Koo Kang, T. Van Dao, E. D. De Toni and 21 more. NEJM Evidence, 2022

1,114 citations recorded by the source corpus.

Tremelimumab/Durvalumab for Hepatocellular CarcinomaThis trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional therapy. Median OS increased significantly by 2.5 months (16.4 vs. 13.8) with single-dose tremelimumab plus durvalumab treatment every 4 weeks versus sorafenib alone.

Subfields: Hepatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c5262a7bbaba1548d230e455cd38f641ce5faef7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Amit G. Singal
2. F. Kanwal
3. J. Llovet
4. Jordi Bruix1 , 2
5. Riccardo Lencioni

In Oncology

1. J. Llovet

In Pathology and Forensic Medicine

1. J. Llovet
2. F. Kanwal

Citations in the corpus

• Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, background): “atezolizumab plus bevacizumab and durvalumab plus tremelimumab compared with camrelizumab plus rivoceranib (grade 3–4 in 43% and 26% versus 81% of patients, respectively) 177,178,186,234 .”